Castle Biosciences (CSTL) Short term Debt (2019 - 2026)

Castle Biosciences (CSTL) has 6 years of Short term Debt data on file, last reported at $1.7 million in Q1 2026.

• Quarterly Short term Debt rose 50.05% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (up 50.05% YoY) and the FY2025 annual result came in at $417000.0, up 50.0% from the prior year.
• Short term Debt advanced to $1.7 million in Q1 2026 per CSTL's latest filing, from $417000.0 in the prior quarter.
• The five-year high for Short term Debt was $20.8 million in Q1 2022, with the low at $278000.0 in Q4 2024.
• Average Short term Debt over 4 years is $4.4 million, with a median of $1.4 million recorded in 2025.
• Year-over-year, Short term Debt surged 50.0% in 2025 and soared 50.05% in 2026.
• Castle Biosciences' Short term Debt stood at $20.8 million in 2022, then tumbled by 98.67% to $278000.0 in 2024, then surged by 50.0% to $417000.0 in 2025, then surged by 299.76% to $1.7 million in 2026.
• Business Quant data shows CSTL's Short term Debt at $1.7 million in Q1 2026, $417000.0 in Q4 2025, and $1.9 million in Q2 2025.